YDES
YD Bio Limited Ordinary Shares
NASDAQ · Healthcare · Biotechnology · TW
$3.54
−3.54%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+21.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Chang Kochi · director | A-Award | 5,749 | $0.00 |
| Jul 1, 2026 | Lu Shao-Ta · director | M-Exempt | 5,749 | $0.00 |
| Jul 1, 2026 | Lu Shao-Ta · director | A-Award | 5,749 | $0.00 |
| Jul 1, 2026 | Chang Kochi · director | M-Exempt | 5,749 | $0.00 |
| Apr 2, 2026 | Lu Shao-Ta · director | M-Exempt | 2,081 | $0.00 |
| Apr 2, 2026 | Lu Shao-Ta · director | A-Award | 2,081 | $0.00 |
| Apr 2, 2026 | Chang Kochi · director | M-Exempt | 2,081 | $0.00 |
| Apr 2, 2026 | Chang Kochi · director | A-Award | 2,081 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 0Increased 6Reduced 1Sold out 7
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 60,236 | May 15, 2026 |
| CERITY PARTNERS LLC | Unchanged | 32,406 | May 15, 2026 |
| CYPRESS CAPITAL MANAGEMENT LLC (WY) | Increased | 30,690 | May 8, 2026 |
| CITADEL ADVISORS LLC | Increased | 30,106 | Sep 2, 2026 |
| CITADEL ADVISORS LLC | Increased | 19,450 | May 15, 2026 |
| UBS GROUP AG | Increased | 11,628 | May 5, 2026 |
| WOLVERINE ASSET MANAGEMENT LLC | Increased | 4,886 | May 4, 2026 |
| MORGAN STANLEY | Reduced | 223 | May 15, 2026 |
| FMR LLC | Unchanged | 1 | May 15, 2026 |
| MORGAN STANLEY | Sold Out | 0 | May 15, 2026 |
| UBS Group AG | Sold Out | 0 | May 5, 2026 |
| FMR LLC | Sold Out | 0 | May 15, 2026 |
| WOLVERINE ASSET MANAGEMENT LLC | Sold Out | 0 | May 4, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Sold Out | 0 | May 15, 2026 |
| Cerity Partners LLC | Sold Out | 0 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 1, 2026